Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “inhibitors”

2,466 pharma patents match "inhibitors" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 2,466
Index total 30,257
Page 5 / 103

Quick answer

This filtered view shows 2,466 pharmaceutical patents matching "inhibitors" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

2,466 results for “inhibitors” · 30,257 patents in full index Clear search

  1. US 12219327

    Substituted isoindolines as PI3K-alpha inhibitors

    Relay Therapeutics, Inc. · Granted Feb 4, 2025 · Expires Jan 30, 2045

    granted
  2. US 12209085

    RET inhibitors, pharmaceutical compositions and uses thereof

    SUNSHINE LAKE PHARMA CO., LTD. · Granted Jan 28, 2025 · Expires Jan 23, 2045

    granted
  3. US 12202845

    Ras inhibitors

    Revolution Medicines, Inc. · Granted Jan 21, 2025 · Expires Jan 16, 2045

    granted
  4. US 12201617

    HDAC6 inhibitors for treatment of metabolic disease and HFpEF

    Tenaya Therapeutics, Inc. · Granted Jan 21, 2025 · Expires Jan 16, 2045

    granted
  5. US 12186324

    Imidazopiperazine inhibitors of transcription activating proteins

    The Board of Regents of the University of Texas System · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  6. US 12187754

    LpxC inhibitors and uses thereof

    BLACKSMITH MEDICINES, INC. · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  7. US 12186313

    Pyridazinone compounds and their use as DAAO inhibitors

    Takeda Pharmaceutical Company Limited · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  8. US 12187694

    SLC26A3 inhibitors and use thereof

    The Regents of the University of California · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  9. US 12187792

    IL-4/IL-13 pathway inhibitors for enhanced efficacy in treating cancer

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  10. US 12187731

    Compounds useful as inhibitors of ATR kinase

    Vertex Pharmaceuticals Incorporated · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  11. US 12187746

    C26-linked rapamycin analogs as mTOR inhibitors

    Revolution Medicines, Inc. · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  12. US 12171741

    2,3-dihydrobenzo[b]thiophene derivatives as hypoxia inducible factor-2(alpha) inhibitors

    NIKANG THERAPEUTICS, INC. · Granted Dec 24, 2024 · Expires Dec 19, 2044

    granted
  13. US 12171760

    Use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors

    Corcept Therapeutics Incorporated · Granted Dec 24, 2024 · Expires Dec 19, 2044

    granted
  14. US 12171765

    Combination therapies using PRMT5 inhibitors for the treatment of cancer

    Mirati Therapeutics, Inc. · Granted Dec 24, 2024 · Expires Dec 19, 2044

    granted
  15. US 12168023

    Inhibitors of adenosine 5′-nucleotidase

    Arcus Biosciences, Inc. · Granted Dec 17, 2024 · Expires Dec 12, 2044

    granted
  16. US 12162877

    Human dihydroorotate dehydrogenase (hDHODH) inhibitors and their use in targeting oncological diseases sensitive to pyrimidine starvation

    DRUG DISCOVERY AND CLINIC S.R.L. · Granted Dec 10, 2024 · Expires Dec 5, 2044

    granted
  17. US 12162838

    Human plasma kallikrein inhibitors

    BioCryst Pharmaceuticals, Inc. · Granted Dec 10, 2024 · Expires Dec 5, 2044

    granted
  18. US 12162818

    Inhibitors of the n-terminal domain of the androgen receptor

    The United States Government represented by the Department of Veterans Affairs · Granted Dec 10, 2024 · Expires Dec 5, 2044

    granted
  19. US 12157891

    Treatment of uveitis with endoplasmic reticulum aminopeptidase 1 (ERAP1) inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 3, 2024 · Expires Nov 28, 2044

    granted
  20. US 12156880

    Heterocyclic RIP1 kinase inhibitors

    Rigel Pharmaceuticals, Inc. · Granted Dec 3, 2024 · Expires Nov 28, 2044

    granted
  21. US 12156879

    Combining BACE1 inhibitors with mGluR agonists for Alzheimer's disease therapy

    UNIVERSITY OF CONNECTICUT · Granted Dec 3, 2024 · Expires Nov 28, 2044

    granted
  22. US 2024390317

    COMBINATION TREATMENT AND/OR PREVENTION OF CARDIAC DISEASES IN NON-HUMAN MAMMALS COMPRISING ONE OR MORE SGLT-2 INHIBITORS AND PIMOBENDAN AND/OR TELMISARTAN

    BOEHRINGER INGELHEIM VETMEDICA GMBH [DE] · Granted Nov 28, 2024 · Expires Nov 23, 2044

    granted
  23. US 2024390332

    Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more SGLT-2 inhibitors and telmisartan

    BOEHRINGER INGELHEIM VETMEDICA GMBH [DE] · Granted Nov 28, 2024 · Expires Nov 23, 2044

    granted
  24. US 12152034

    FGFR inhibitors and methods of making and using the same

    Relay Therapeutics, Inc. · Granted Nov 26, 2024 · Expires Nov 21, 2044

    granted